Repare Therapeutics Inc. (RPTX) Research

Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments. Central to their efforts is the proprietary, genome-wide, and CRISPR-enabled SNIPRx platform, which systematically uncovers and advances highly targeted cancer medicines. These therapies are specifically designed to address genomic instability, particularly related to DNA damage repair mechanisms. Their primary investigational drug is RP-3500, an oral small molecule inhibitor currently being developed to treat solid tumors that possess specific genomic alterations linked to DNA damage repair. Repare is also advancing RP-6306, which is in Phase I clinical trials for tumors characterized by genetic alterations involving CCNE1 amplification. Furthermore, the company is pursuing a Polymerase Theta program, investigating a synthetic lethal target relevant to BRCA mutations and other genomic abnormalities. Repare Therapeutics Inc. was established in 2016 and maintains its headquarters in Montreal, Canada.

Market snapshot

Symbol
RPTX
Price
$2.65
Day change
0.00%
Market cap
$114.2M
P/E ratio
-1.58x
52-week range
0.89-2.66
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$16.00

Peer companies

  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • ALX Oncology Holdings Inc. (ALXO)
  • aTyr Pharma, Inc. (ATYR)
  • Biomea Fusion, Inc. (BMEA)
  • CAMP4 Therapeutics Corporation (CAMP)
  • Precision BioSciences, Inc. (DTIL)
  • Fractyl Health, Inc. Common Stock (GUTS)
  • Immunic, Inc. (IMUX)

Recent insider activity

  • BVF PARTNERS L P/IL — U-Tender (548938 shares) on 2026-01-28
  • SCHAFER CAROL — D-Return (8000 shares) on 2026-01-28
  • SCHAFER CAROL — D-Return (37941 shares) on 2026-01-28
  • RHOADS ANN D — D-Return (4000 shares) on 2026-01-28
  • Civik Thomas — D-Return (7500 shares) on 2026-01-28

Open Repare Therapeutics Inc. (RPTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.